Influence of dipyridamole on expression of PAC-1 and CD62p in patients with malignant lymphoma.
- Author:
Ya-Jun JIANG
1
;
Xiu-Mei LI
;
Hong-Xia WANG
;
Li-Li KANG
;
Gui-Hua ZHU
;
Wan-Chuan ZHUANG
Author Information
1. Department of Hematology, Lianyungang Hospital of Bengbu Medical College, The Second People Hospital of Lianyungang, Lianyungang 222002, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Dipyridamole;
therapeutic use;
Dual Specificity Phosphatase 2;
metabolism;
Female;
Fibrinogen;
metabolism;
Humans;
Lymphoma;
blood;
drug therapy;
Male;
Middle Aged;
P-Selectin;
metabolism;
Platelet Activation;
Young Adult
- From:
Journal of Experimental Hematology
2010;18(4):923-926
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to explore the expressions of platelet-activated markers PAC-1 and CD62p in peripheral blood of malignant lymphoma patients and the influence of dipyridamole on their expression. 32 lymphoma patients were divided into simple chemotherapy group (simple group) and chemotherapy plus dipyridamole group (combined group) randomly, and 15 healthy peoples were selected as control group. The dipyridamole of 100 mg/day was given to the patients in combined group. The expression levels of PAC-1, CD62p and fibrinogen (Fib) were detected by flow cytometry and magnetic bead method on day 0, 3, 7 and 14 of chemotherapy respectively. The results showed that the levels of PAC-1, CD62p and Fib in lymphoma patients were significantly higher than those in control group (p < 0.01, 0.05), moreover there was positive correlation between levels of PAC-1 and Fib (r = 0.549, p < 0.01). PAC-1 expression on day 0 and 3 of chemotherapy in simple group was higher than that on day 14 (p < 0.05, 0.01) and CD62p expression on day 3 of chemotherapy was higher than that on day 0, 7 and 14 (p < 0.05, 0.01). PAC-1 expression in combined group on day 14 of chemotherapy was lower than than on day 0 and 3 (p < 0.05, 0.01), and CD62p on day 14 was lower than that on day 3 of chemotherapy (p < 0.05); PAC-1 and CD62p expressions in combined group on day 3, 7 and 14 of chemotherapy were decreased than those in simple group, but Fib level was not changed significantly. It is concluded that the patients with malignant lymphoma usually accompany with platelet activation and hyperfibrinogenemia in peripheral blood. Applying dipyridamole routine dosage in chemotherapy can efficiently restrain platelet activation.
